每(mei)經(jing)AI快(kuai)訊(xun)，1月23日，長(chang)藥控股(gu)公(gong)(gong)(gong)告(gao)稱，根據初(chu)步測算，預(yu)(yu)計(ji)公(gong)(gong)(gong)司2024年(nian)(nian)度期末歸(gui)屬于上市(shi)公(gong)(gong)(gong)司股(gu)東的(de)所有者(zhe)權益為(wei)-37,000萬(wan)元至(zhi)-55,000萬(wan)元。根據相(xiang)關規定，若(ruo)上市(shi)公(gong)(gong)(gong)司出現(xian)“最(zui)近一個會(hui)計(ji)年(nian)(nian)度經(jing)審計(ji)的(de)期末凈資(zi)產(chan)為(wei)負(fu)(fu)值(zhi)”的(de)情形，其(qi)股(gu)票(piao)(piao)交易(yi)將(jiang)(jiang)被(bei)(bei)實施(shi)(shi)退(tui)市(shi)風險(xian)(xian)警示(shi)。如果(guo)公(gong)(gong)(gong)司2024年(nian)(nian)度經(jing)審計(ji)的(de)期末凈資(zi)產(chan)為(wei)負(fu)(fu)值(zhi)，公(gong)(gong)(gong)司股(gu)票(piao)(piao)交易(yi)將(jiang)(jiang)在(zai)2024年(nian)(nian)年(nian)(nian)度報告(gao)披露(lu)后被(bei)(bei)實施(shi)(shi)退(tui)市(shi)風險(xian)(xian)警示(shi)。此(ci)外，公(gong)(gong)(gong)司已啟動預(yu)(yu)重(zhong)(zhong)整(zheng)(zheng)，但能否進入重(zhong)(zhong)整(zheng)(zheng)程序存在(zai)不確定性。如果(guo)法(fa)院裁定受理重(zhong)(zhong)整(zheng)(zheng)申請(qing)，公(gong)(gong)(gong)司股(gu)票(piao)(piao)交易(yi)將(jiang)(jiang)被(bei)(bei)實施(shi)(shi)退(tui)市(shi)風險(xian)(xian)警示(shi)。即使法(fa)院正式受理重(zhong)(zhong)整(zheng)(zheng)申請(qing)，后續仍存在(zai)因重(zhong)(zhong)整(zheng)(zheng)失敗而被(bei)(bei)宣告(gao)破(po)產(chan)并(bing)被(bei)(bei)實施(shi)(shi)破(po)產(chan)清算的(de)風險(xian)(xian)。如果(guo)公(gong)(gong)(gong)司因重(zhong)(zhong)整(zheng)(zheng)失敗而被(bei)(bei)宣告(gao)破(po)產(chan)，公(gong)(gong)(gong)司股(gu)票(piao)(piao)將(jiang)(jiang)面(mian)臨被(bei)(bei)終止上市(shi)的(de)風險(xian)(xian)。